LUCD

Lucid Diagnostics Inc

Add to Watchlist

Advanced Chart

1.100

-0.02(-1.786%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.135

Open

1.110

VWAP

1.12

Vol

728.04K

Mkt Cap

119.01M

Low

1.095

Amount

812.59K

EV/EBITDA(TTM)

Total Shares

52.42M

183.16M

EV/OCF(TTM)

P/S(TTM)

15.15

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. It is also developing EsoCure, is an Esophageal Ablation Device, which is a technology that allows a clinician to treat dysplastic BE.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

1.15M

+17.33%

1.77M

+51.44%

2.61M

+118.1%

Estimates Revision

The market is revising Downward the revenue expectations for Lucid Diagnostics Inc. (LUCD) for FY2025, with the revenue forecasts being adjusted by -24.26% over the past three months. During the same period, the stock price has changed by -17.29%.

Revenue Estimates for FY2025

Revise Downward

-24.26%

In Past 3 Month

Stock Price

Go Down

-17.29%

In Past 3 Month

6 Analyst Rating

244.55% Upside

Wall Street analysts forecast LUCD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LUCD is 3.79 USD with a low forecast of 2.00 USD and a high forecast of 7.75 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

244.55% Upside

Current: 1.100

Low

2.00

Averages

3.79

High

7.75

244.55% Upside

Current: 1.100

Low

2.00

Averages

3.79

High

7.75

Ascendiant

Buy

maintain

2025-06-06

Reason

Ascendiant

Price Target

2025-06-06

maintain

Buy

Reason

Ascendiant Capital

Edward Woo

Strong Buy

Maintains

$7 → $7.5

2025-04-21

Reason

Ascendiant Capital

Edward Woo

Price Target

$7 → $7.5

2025-04-21

Maintains

Strong Buy

Reason

Needham

Mike Matson

Strong Buy

Reiterates

2025-04-11

Reason

Needham

Mike Matson

Price Target

2025-04-11

Reiterates

Strong Buy

Reason

Cantor Fitzgerald

Ross Osborn

Buy

Reiterates

2025-03-26

Reason

Cantor Fitzgerald

Ross Osborn

Price Target

2025-03-26

Reiterates

Buy

Reason

Needham

Mike Matson

Strong Buy

Maintains

$2.5 → $3

2025-03-24

Reason

Needham

Mike Matson

Price Target

$2.5 → $3

2025-03-24

Maintains

Strong Buy

Reason

Ascendiant Capital

Edward Woo

Strong Buy

Maintains

$7.25 → $7

2024-12-09

Reason

Ascendiant Capital

Edward Woo

Price Target

$7.25 → $7

2024-12-09

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Lucid Diagnostics Inc (LUCD.O) is -2.43, compared to its 5-year average forward P/E of -2.00. For a more detailed relative valuation and DCF analysis to assess Lucid Diagnostics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.00

Current PE

-2.43

Overvalued PE

0.05

Undervalued PE

-4.05

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.46

Current EV/EBITDA

-4.44

Overvalued EV/EBITDA

0.20

Undervalued EV/EBITDA

-5.12

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

27.40

Current PS

15.28

Overvalued PS

75.11

Undervalued PS

-20.31

Financials

Annual

Quarterly

FY2025Q1

YoY :

-17.28%

828.00K

Total Revenue

FY2025Q1

YoY :

+15.71%

-12.49M

Operating Profit

FY2025Q1

YoY :

+153.56%

-26.91M

Net Income after Tax

FY2025Q1

YoY :

+30.00%

-0.52

EPS - Diluted

FY2025Q1

YoY :

-0.72%

-12.56M

Free Cash Flow

FY2025Q1

YoY :

-2.53%

-100.00

Gross Profit Margin - %

FY2025Q1

YoY :

-17.12%

-1.07K

FCF Margin - %

FY2025Q1

YoY :

+206.54%

-3.25K

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

457.6K

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

457.6K

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

LUCD News & Events

Events Timeline

2025-05-27 (ET)

2025-05-27

07:33:17

Lucid Diagnostics to join Russell 2000, Russell 3000 indexes

2025-05-14 (ET)

2025-05-14

08:04:16

Lucid Diagnostics reports Q1 adjusted EPS (16c), consensus (10c)

2025-04-24 (ET)

2025-04-24

08:08:23

Lucid Diagnostics' EsoGuard DNA Test shows cancer detection efficacy in study

News

1.0

07-16SeekingAlpha

Lucid says meeting scheduled to determine Medicare coverage for cancer test

7.0

07-16Newsfilter

MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test

4.5

07-03CNBC

5 things to know before the stock market opens Thursday

People Also Watch

WWR

Westwater Resources Inc

Spero Therapeutics Inc

Nine Energy Service Inc

Li Bang International Corporation Inc

Bluerock Homes Trust Inc

FAQ

What is Lucid Diagnostics Inc (LUCD) stock price today?

The current price of LUCD is 1.1 USD — it has decreased -1.79 % in the last trading day.

LUCD

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

LUCD News & Events

Events Timeline

News

People Also Watch

FAQ

What is Lucid Diagnostics Inc (LUCD) stock price today?

What is Lucid Diagnostics Inc (LUCD)'s business?

What is the price predicton of LUCD Stock?

What is Lucid Diagnostics Inc (LUCD)'s revenue for the last quarter?

What is Lucid Diagnostics Inc (LUCD)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Lucid Diagnostics Inc (LUCD)'s fundamentals?

How many employees does Lucid Diagnostics Inc (LUCD). have?

What is Lucid Diagnostics Inc (LUCD) market cap?